Expression of viral genes in tumour cells of the virus-assothe treatment of undifferentiated nasopharyngeal carciciated cancers could provide highly selective ways of tarnoma, a cancer that always contains Epstein-Barr virus geting expression of therapeutic vectors to the tumour in the tumour cells. 2 on clear differences between tumour cells and normal cells. These tumour-specific markers can take the form of Expression of EBNA-1 in EBV-associated cancers is of particular interest because EBNA-1 is known to transcell proteins that are differentially expressed (thus permitting immunological selectivity) or cell functions that activate gene expression, increase transfection efficiency and enable DNA replication of plasmids via a well permit selective activation of a therapeutic agent in the tumour cells. A key problem with this approach is the defined DNA sequence called oriP. [3] [4] [5] [6] [7] The normal function of oriP in Epstein-Barr virus is as the origin of repliextent to which the marker is restricted to tumour cells.
Strategies to target therapeutics to tumour cells depend EBV-associated cases of Burkitt's lymphoma and nasopharyngeal carcinoma. 2 on clear differences between tumour cells and normal cells. These tumour-specific markers can take the form of Expression of EBNA-1 in EBV-associated cancers is of particular interest because EBNA-1 is known to transcell proteins that are differentially expressed (thus permitting immunological selectivity) or cell functions that activate gene expression, increase transfection efficiency and enable DNA replication of plasmids via a well permit selective activation of a therapeutic agent in the tumour cells. A key problem with this approach is the defined DNA sequence called oriP. [3] [4] [5] [6] [7] The normal function of oriP in Epstein-Barr virus is as the origin of repliextent to which the marker is restricted to tumour cells.
Approximately 15% of all human cancer is virus-assocation for the maintenance of the virus in EBV-transformed cells. EBNA-1 is a sequence-specific DNA binding ciated. 1 Several of the viruses that are linked with human cancers persist in the normal human host in only a very protein 8, 9 and oriP is composed of multiple copies of a 30 bp sequence which contains the binding site for EBNA-1 small number of cells with a low viral load. Thus the presence of the virus in tumour cells in patients with (the family of repeats, FR) spaced about 1 kb away from four further repeated sequences which also contain the virus-associated cancers constitutes an exceptionally favourable tumour-specific marker. In principle, viral EBNA-1 binding site (the dyad symmetry element, DS). The family of repeats (FR) part of oriP is sufficient for proteins expressed in these tumours might constitute very specific targets for immunotherapy of the tumours the transcription enhancer activity but not for replication. 3 The mechanisms by which the EBNA-1-depenbut selection events that may have occurred in the development of the tumour frequently prevent this approach. dent transcription enhancer activity of oriP is mediated are unknown but it is clear that it is important for the For example, in many tumours MHC class I gene expression and antigen presentation are down-regulated, activity of the EBV Cp promoter (which directs expression of the EBNA genes) and the promoter for effectively preventing recognition of the tumour cells by cytotoxic T lymphocytes that might be directed to kill the LMP1. 10, 11 These are located about 3.5 kb and 10.5 kb, respectively, on opposite sides of the oriP element in the tumour cells. Nevertheless, expression of certain viral genes is characteristic of the tumour state in many of the EBV genome. 12 There has been a recent report proposing the use of EBV-based vectors to maintain expression of virus-associated cancers. For example, the HPV E6 and E7 genes are normally expressed in HPV-positive cervical genes of interest in human cells, particularly lymphocytes 13 but in this article we consider particularly the cancer (the tumour cells carry HPV in about 90% of cervical cancer cases) and the EBNA-1 protein and EBER prospect of using oriP vectors dependent on EBNA-1 present in the target cells for therapy of EBV-related canRNAs are normally expressed in all tumour cells in the cers. Experiments using model promoters (for example the HSV thymidine kinase promoter) linked to the FR part fected. 3, 6 This is illustrated for another cell type in Figure  1 , where 293 cells constitutively expressing EBNA-1 have an eight-fold higher activity of a CAT reporter from the plasmid pFRTKCAT than the same cells lacking EBNA-1. 293 Cells are derived from human kidney so the ability of EBNA-1 to activate the oriP enhancer is not restricted to lymphoid cells.
Plasmids containing the whole oriP element can also be selectively introduced into cells containing the EBNA-1 protein through the enhanced transfection frequency of these cells, perhaps because the ability of the plasmid to replicate bypasses the rare integration events that are normally required for stable transfection of cells. 4 Thus, a plasmid containing oriP, a gene encoding resistance to hygromycin and the HSV thymidine kinase gene established transfected hygromycin resistant colonies at a 10-fold higher frequency in 293 cells expressing EBNA-1 than in the control 293 cells. The thymidine kinase gene (Figure 3b ). The Cp promoter sumably be obtained by combining the enhanced uptake of plasmid mediated by EBNA-1 with a highly EBNA-1-is clearly well adapted to function in lymphocytes, where it is expressed in the normal EBV life cycle, but there is dependent promoter driving expression of the toxic gene. The optimal promoter has yet to be identified but the also significant activity of Cp in the epithelial cells in this system (Figure 3b ) where a 25-fold activation by EBNA-EBV Cp promoter 14 has interesting properties that might make it suitable. Comparison of various Cp promoter 1 was observed. However, a further screen of a wide variety of different promoters linked to oriP will be constructs with and without oriP show that not only does oriP enhance the activity of the Cp promoter in cells conimportant to search for other promoters that might be even more dependent on oriP for their activity in epitaining EBNA-1, it also reduces Cp activity in cells lacking EBNA-1 (Figure 3 and Refs 15 and 16). These properthelial cells. Epithelial cells are important in this context because one of the most attractive targets for an EBNAties are shown both in cotransfection assays with EBNA-1-specific targeted gene therapeutic strategy would be the epithelial cells of nasopharyngeal carcinoma. Persistence of the oriP plasmid through EBNA-1-dependent replication in EBV-infected cells also has the potential for improving the differential in promoter activity between EBV-infected and uninfected cells. This is illustrated in Figure 4 , where the oriP plasmid response in EBV-negative cells after transfection declines as the cells are passaged but persists in the EBNA-1-positive cells. If a therapeutic plasmid expressed an enzyme that converted a prodrug to an active agent, delaying the administration of the prodrug so that the plasmid level could decline in the EBV-negative cells would increase the selectivity for the EBV-positive cells. After 10 days in culture following the transfection, there was a 108-fold difference in reporter gene activity comparing the cells with and without EBNA-1 (Figure 4) .
Other cancers in which EBV-directed therapeutic stra- lance is not possible in AIDS so the novel EBNA-1-cancer cells and illustrated the feasibility of this using plasmids transfected into cell lines and the thymidine directed strategy might be useful in that context. In 40% of cases of Hodgkin's lymphoma, the Reed-Sternberg kinase/ganciclovir system for killing the cells. There are many different potential therapeutic systems for acticells are found to contain EBV and express EBNA-1 2 so these cases may constitute another attractive target for vation of cytotoxic agents in tumour cells 18 and the EBV lytic cycle transactivator BZLF1 has also been proposed such an approach.
In this article we have outlined an approach which as a therapeutic gene expressed from an oriP plasmid. 19 
